Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1094 | 1020 | 1115 | 1111 | 1340 | 1754 |
Fund Return | 9.36% | 2.05% | 11.49% | 3.58% | 6.03% | 5.78% |
Place in category | 292 | 175 | 413 | 88 | 47 | 23 |
% in Category | 69 | 44 | 95 | 18 | 12 | 8 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Weitz Value Investor | 563.51M | 12.66 | 4.09 | 9.39 | ||
Weitz Partners III Opportunity Inst | 434.09M | 16.26 | 1.89 | 5.58 | ||
Weitz Value Institutional | 401.25M | 12.84 | 4.25 | 9.60 | ||
Weitz Partners Value Institutional | 358.49M | 15.80 | 2.55 | 6.33 | ||
Weitz Partners Value Investor | 234.31M | 22.58 | 6.18 | 6.64 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Vanguard Wellesley Income Admiral | 40.46B | 5.97 | 1.08 | 5.26 | ||
Vanguard Tax-Managed Balanced Adm | 10.36B | 12.17 | 4.21 | 7.50 | ||
Vanguard LifeStrategy Cnsrv Gr Inv | 10.18B | 7.54 | 0.93 | 4.82 | ||
Vanguard Wellesley Income Inv | 8.5B | 5.92 | 1.01 | 5.19 | ||
BlackRock Multi-Asset Income Instl | 5.89B | 7.39 | 1.79 | 4.27 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Berkshire Hathaway B | US0846707026 | 2.60 | 472.56 | +0.70% | |
Danaher | US2358511028 | 2.44 | 222.84 | -0.40% | |
Aon | IE00BLP1HW54 | 2.42 | 370.38 | +0.99% | |
Thermo Fisher Scientific | US8835561023 | 2.26 | 607.12 | +6.84% | |
Mastercard | US57636Q1040 | 2.17 | 572.01 | +4.23% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Sell | Neutral | Buy |
Technical Indicators | Strong Buy | Strong Sell | BUY |
Summary | Neutral | Sell | Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review